Optimizing pediatric dosing: A developmental pharmacologic approach

Pharmacotherapy

Volumn 29, Issue 6, 2009, Pages 680-690

  Anderson, Gail D ^a   Lynn, Anne M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Children; CYP; Cytochrome P450; Dosing; Infants; Neonates; Pediatrics; Pharmacokinetics

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIMIGRAINE AGENT; ANTITUSSIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; FEXOFENADINE; GABAPENTIN; GANCICLOVIR; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LINEZOLID; MIDAZOLAM; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PHENOBARBITAL; PHENYTOIN; PROPOFOL; PROTON PUMP INHIBITOR; UNINDEXED DRUG;

DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FIRST PASS EFFECT; KIDNEY CLEARANCE; PHARMACOKINETICS; REVIEW; URINARY EXCRETION;

AGE FACTORS; ARYLAMINE N-ACETYLTRANSFERASE; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; INFANT, NEWBORN; ISOENZYMES; KIDNEY; LIVER; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 66749129281     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.6.680     Document Type: Review

References (111)

1. Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005;59(6):663-669 (Pubitemid 40835498)
2. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006;45(11):1077-1097 (Pubitemid 44631388)
3. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008;48:303-332
4. Anderson G. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-563 (Pubitemid 28232761)
5. Yan Z, Caldwell GW. Metabolism profiling, and cytochrome P450 inhibition and induction in drug discovery. Curr Top Med Chem 2001;1(5):403-425
6. Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002;91(9):1923-1935 (Pubitemid 36254929)
7. Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004;57(4):473-486 (Pubitemid 38519653)
8. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005;44(10):989-1008. (Pubitemid 41356388)
9. Al Za'abi M, Lanner A, Xiaonian X, Donovan T, Charles B. Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. Ther Drug Monit 2006;28(6):793-799
10. Jalling B. Plasma and cerebrospinal fluid concentrations of phenobarbital in infants given single doses. Dev Med Child Neurol 1974;11:781-793
11. Frenkel LM, Capparelli EV, Dankner WM, et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The pediatric AIDS clinical trials group. J Infect Dis 2000;182(6):1616-1624
12. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001;31(8-9):469-497 (Pubitemid 32826389)
13. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002;53(4):390-392
14. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27(8):866-871 (Pubitemid 29347585)
15. Matsushima S, Maeda K, Hayashi H, et al. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 2008;73(5):1474-1483
16. Krishna R, Krishnaswami S, Kittner B, Sankoh AJ, Jensen BK. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004;25(9):373-387 (Pubitemid 40028410)
17. Hayani KC, Hatzopoulos FK, Frank AL, et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatr 1997;131(1 pt 1):76-80. (Pubitemid 27498312)
18. Kearns GL, Jungbluth GL, Abdel-Rahman SM, et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003;74(5):413-422 (Pubitemid 37357720)
19. Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994;80(1):104-122 (Pubitemid 24033610)
20. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002;43(suppl 3):53-59 (Pubitemid 34633697)
21. Morgan DJ, Smallwood RA. Clinical significance of pharmacokinetic models of hepatic elimination. Clin Pharmacokinet 1990;18(1):61-76. (Pubitemid 20040338)
22. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006;45(9):931-956 (Pubitemid 44299829)
23. Miners JO, McKinnon RA. CYP1A. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2000:61-73.
24. Aranda JV, Collinge JM, Zinman R, Watters G. Maturation of caffeine elimination in infancy. Arch Dis Child 1979;54(12):946-949 (Pubitemid 10174351)
25. Lambert GH, Schoeller DA, Kotake AN, Flores C, Hay D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther 1986;9(6):375-388 (Pubitemid 17213887)
26. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005;59(6):691-704. (Pubitemid 40835503)
27. Frazier JA, Cohen LG, Jacobsen L, et al. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 2003;23(1):87-91. (Pubitemid 36164429)
28. Daviss WB, Perel JM, Rudolph GR, et al. Steady-state pharmacokinetics of bupropion SR in juvenile patients. J Am Acad Child Adolesc Psychiatry 2005;44(4):349-357 (Pubitemid 40393273)
29. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 2001;41(7):770-778 (Pubitemid 32612441)
30. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004;308(3):965-974 (Pubitemid 38263972)
31. Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 1997;7(6):441-452 (Pubitemid 27517572)
32. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000;68(5):541-555
33. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolites. Drug Metab Dispos 1996;24:1401-1403 (Pubitemid 26427180)
34. Suzuki Y, Mimaki T, Cox S, Koepke J, Hayes J, Walson PD. Phenytoin age-dose-concentration relationship in children. Ther Drug Monit 1994;16:145-150 (Pubitemid 24096619)
35. Stempak D, Gammon J, Klein J, Koren G, Baruchel S. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther 2002;72(5):490-497 (Pubitemid 36237719)
36. Tran A, Rey E, Pons G, et al. Pharmacokineticpharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002;71(5):359-367 (Pubitemid 34518146)
37. Kearns GL, Andersson T, James LP, et al. Omeprazole disposition in children following single-dose administration. J Clin Pharmacol 2003;43(8):840-848 (Pubitemid 36886104)
38. Marier JF, Dubuc MC, Drouin E, Alvarez F, Ducharme MP, Brazier JL. Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. Ther Drug Monit 2004;26(1):3-8. (Pubitemid 38140903)
39. Heyman MB, Zhang W, Huang B, Chiu YL, Amer F, Winter HS. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;44(1):35-40. (Pubitemid 46071789)
40. Shimada T, Yamazaki H, Mimura M, Inui T, Guengerich FP. Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with the microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423 (Pubitemid 24229655)
41. Blake MJ, Gaedigk A, Pearce RE, et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007;81(4):510-516
42. Park J, Kim K, Park P, et al. Effect of age on the activity of cytochrome P450 2D6 using dextromethorphan phenotyping in humans [abstract]. Clin Pharmacol Ther 2005;77:P24.
43. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinet ics in chi ldren and adolescents wi th attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003;13(1):53-63. (Pubitemid 36570188)
44. Wilens TE, Cohen L, Biederman J, et al. Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 2002;22(6):568-575 (Pubitemid 35416782)
45. Findling RL, Nucci G, Piergies AA, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 2006;31(6):1274-1285 (Pubitemid 43971843)
46. Aman MG, Vinks AA, Remmerie B, et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 2007;29(7):1476-1486 (Pubitemid 47348123)
47. Wrighton SA, Stevens JC. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
48. Johnson TN, Tucker GT, Rostami-Hodjegan A. Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther 2008;83(5):670-671
49. Kearns GL, Robinson PK, Wilson JT, et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther 2003;74(4):312-325 (Pubitemid 37222852)
50. Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001;41(12):1359-1369 (Pubitemid 33104904)
51. Fanta S, Jonsson S, Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007;64(6):772-784 (Pubitemid 350222065)
52. Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005;9(2):162-169 (Pubitemid 40476842)
53. Flynn JT, Nahata MC, Mahan JD Jr, Portman RJ. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol 2006;46(8):905-916 (Pubitemid 44050827)
54. Yukawa E, Satou M, Nonaka T, et al. Influence of age and comedication on steady-state clonazepam serum level-dose ratios in Japanese epileptic patients. J Clin Pharm Ther 2001;26(5):375-379 (Pubitemid 32989560)
55. Battino D, Bossi L, Croci D, et al. Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy. Ther Drug Monit 1980;2(4):315-322 (Pubitemid 11142011)
56. Albani F, Riva R, Contin M, Baruzzi A. A within-subject analysis of carbamazepine disposition related to development in children with epilepsy. Ther Drug Monit 1992;14(6):457-460
57. Jullien V, Urien S, Hirt D, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 2006;50(11):3548-3555 (Pubitemid 44684864)
58. Verweel G, Burger DM, Sheehan NL, et al. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir Ther 2007;12(4):453-458 (Pubitemid 47044809)
59. Grub S, Delora P, Ludin E, et al. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2002;71(3):122-130 (Pubitemid 34271115)
60. Moodley D, Pillay K, Naidoo K, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol 2001;41(7):732-741 (Pubitemid 32612436)
61. Cummings AJ, Whitelaw AG. A study of conjugation and drug elimination in the human neonate. Br J Clin Pharmacol 1981;12:511-515 (Pubitemid 11059788)
62. Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005;33(7):1027-1035 (Pubitemid 41002785)
63. Kokki H, Karvinen M, Jekunen A. Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. Acta Anaesthesiol Scand 2002;46(2):194-198 (Pubitemid 34250784)
64. Crom WR, Relling MV, Christensen ML, Rivera GK, Evans WE. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther 1991;50(2):132-140
65. Balis FM, Pizzo PA, Eddy J, et al. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 1989;114(5):880-884 (Pubitemid 19122993)
66. Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit 1999;21:182-190 (Pubitemid 29168896)
67. Pariente-Khayat A, Rey E, Gendrel D, et al. Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther 1997;62(4):377-383 (Pubitemid 27475221)
68. Rey E, Gendrel D, Treluyer JM, et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam Clin Pharmacol 2001;15(5):355-359 (Pubitemid 34037826)
69. Moffett BS, Cannon BC, Friedman RA, Kertesz NJ. Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment. Pharmacotherapy 2006;26(12):1687-1693 (Pubitemid 44885325)
70. Taketomo C, Hodding J, Kraus D. Pediatric dosage handbook. Cleveland, OH: Lexi-Comp, 2005.
71. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71(3):115-121 (Pubitemid 34271114)
72. Bosenberg AT, Thomas J, Cronje L, et al. Pharmacokinetics and efficacy of ropivacaine for continuous epidural infusion in neonates and infants. Paediatr Anaesth 2005;15(9):739-749 (Pubitemid 43960890)
73. Berde CB, Yaster M, Meretoja O, et al. Stable plasma concentrations of unbound ropivacaine during postoperative epidural infusion for 24-72 hours in children. Eur J Anaesthesiol 2008;25(5):410-417
74. Saarenmaa E, Neuvonen PJ, Fellman V. Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J Pediatr 2000;136(6):767-770 (Pubitemid 30415651)
75. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel- Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther 2001;70(6):525-531
76. Allegaert K, de Hoon J, Verbesselt R, Naulaers G, Murat I. Maturational pharmacokinetics of single intravenous bolus of propofol. Paediatr Anaesth 2007;17(11):1028-1034 (Pubitemid 47481127)
77. Allegaert K, Peeters MY, Verbesselt R, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth 2007;99(6):864-870
78. Meistelman C, Saint-Maurice C, Lepaul M, Levron JC, Loose JP, Mac Gee K. A comparison of alfentanil pharmacokinetics in children and adults. Anesthesiology 1987;66(1):13-16. (Pubitemid 17218020)
79. Goresky GV, Koren G, Sabourin MA, Sale JP, Strunin L. The pharmacokinetics of alfentanil in children. Anesthesiology 1987;67(5):654-659
80. Roure P, Jean N, Leclerc AC, Cabanel N, Levron JC, Duvaldestin P. Pharmacokinetics of alfentanil in children undergoing surgery. Br J Anaesth 1987;59(11):1437-1440 (Pubitemid 17159345)
81. Wheeler M, Birmingham PK, Lugo RA, Heffner CL, Cote CJ. The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. Anesth Analg 2004;99(5):1347-1351 (Pubitemid 39407279)
82. Paut O, Camboulives J, Viard L, Lemoing JP, Levron JC. Pharmacokinetics of transdermal fentanyl in the perioperative period in young children. Anaesthesia 2000;55(12):1202-1207
83. Knibbe CA, Melenhorst-de Jong G, Mestrom M, et al. Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol 2002;54(4):415-422 (Pubitemid 35334955)
84. Knibbe CA, Zuideveld KP, DeJongh J, Kuks PF, Aarts LP, Danhof M. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther 2002;72(6):670-684 (Pubitemid 36021006)
85. Shangguan WN, Lian Q, Aarons L, et al. Pharmacokinetics of a single bolus of propofol in Chinese children of different ages. Anesthesiology 2006;104(1):27-32.
86. Yerby MS. Treatment of epilepsy during pregnancy. In: Wyllie E, ed. The treatment of epilepsy: principles and practices. Philadelphia: Lea & Febiger, 1993:844-857
87. Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984;17(6):665-669 (Pubitemid 14068498)
88. Anderson GD, Pak C, Doane KW, et al. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother 1997;31(3):279-284 (Pubitemid 27114351)
89. Milsap R, Hill M, Szefler S. Special pharmacokinetic considerations in children. In: Evans WE, Schentag J, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992:10-1-10-32.
90. Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O, Aujard Y. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother 2001;45(1):150-157 (Pubitemid 32039107)
91. Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000;58(3):944-958
92. Wells T, Rippley R, Hogg R, et al. The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol 2001;41(10):1064-1074 (Pubitemid 32880134)
93. Saarenmaa E, Neuvonen PJ, Rosenberg P, Fellman V. Morphine clearance and effects in newborn infants in relation to gestational age. Clin Pharmacol Ther 2000;68(2):160-166 (Pubitemid 30659171)
94. McRorie TI, Lynn AM, Nespeca MK, Opheim KE, Slattery JT. The maturation of morphine clearance and metabolism. Am J Dis Child 1992;146:972-976
95. Kart T, Christrup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children based on a literature review, part 2: clinical use. Paediatr Anaesth 1997;7(2):93-101. (Pubitemid 27241677)
96. Choonara IA, McKay P, Hain R, Rane A. Morphine metabolism in children. Br J Clin Pharmacol 1989;28(5):599-604. (Pubitemid 19273609)
97. Botha JH, du Preez MJ, Miller R, Adhikari M. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. Eur J Clin Pharmacol 1998;53(5):337-341 (Pubitemid 28067974)
98. Marik PE, Havlik I, Monteagudo FS, Lipman J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. J Antimicrob Chemother 1991;27(suppl C):81-89
99. Bowlware KL, McCracken GH Jr, Lozano-Hernandez J, Ghaffar F. Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily. Pediatr Infect Dis J 2006;25(3):208-210 (Pubitemid 43379059)
100. Lang D, von Bernuth G. Serum concentration and serum half-life of digoxin in premature and mature newborns. Pediatrics 1977;59(6):902-906 (Pubitemid 8133809)
101. Zalzstein E, Koren G, Levy M, Bentur Y, MacLeod S, Freedom R. Once-daily versus twice-daily dosing of digoxin in the pediatric age group. J Pediatr 1990;116(1):137-139 (Pubitemid 20038280)
102. Wenning LA, Murphy MG, James LP, et al. Pharmacokinetics of famotidine in infants. Clin Pharmacokinet 2005;44(4):395-406. (Pubitemid 40663684)
103. Kelman AW, Thomson AH, Whiting B, et al. Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol 1984;18(5):685-692 (Pubitemid 15209197)
104. Stolk LM, Degraeuwe PL, Nieman FH, de Wolf MC, de Boer A. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit 2002;24(4):527-531
105. Hogg RJ, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol 2007;22(5):695-701. (Pubitemid 46691526)
106. Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J Pharmacokinet Pharmacodyn 2001;28(6):555-575 (Pubitemid 34289543)
107. de Hoog M, Mouton JW, Schoemaker RC, Verduin CM, van den Anker JN. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. Clin Pharmacol Ther 2002;71(5):349-358 (Pubitemid 34518145)
108. Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis: a population pharmacokinetic study. Br J Clin Pharmacol 2008;65(4):502-510
109. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001;41(9):927-934 (Pubitemid 32786565)
110. Schaible DH, Rocci ML Jr, Alpert GA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis 1986;5(3):304-308 (Pubitemid 16115896)
111. Wrishko RE, Levine M, Khoo D, Abbott P, Hamilton D. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit 2000;22(5):522-531